andreswd Overview My recommendation for Accolade (NASDAQ:ACCD) is a buy rating, as I remain convicted that ACCD can grow 20% in FY25, driven by a strong core demand, health care plan strategy, GLP-1, and elevated demand for expert medical opinion. Note that I previously rated buy rating for ACCD as I expected ACCD to continue executing as guided and growing the business as I expected. As ACCD executes, valuation should re-rate to historical levels. Indeed, I believe the market recognized that valuation was ...